Role of α agonists in treating anaphylaxisBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a600 (Published 08 July 2008) Cite this as: BMJ 2008;337:a600
- Simon T L Hebard, specialist registrar in anaesthesia and critical care,
- Andy J Ball, consultant in anaesthesia and critical care
We were disappointed to see no mention of the Resuscitation Council’s advice regarding the treatment of adrenaline refractory anaphylaxis.1
We agree that early treatment with adrenaline (epinephrine) remains the cornerstone of anaphylaxis management, but it is clear that some patients with cardiovascular collapse fail to respond despite this.1 It is our experience that in such cases, the administration of an intravenous direct acting α agonist (metaraminol, noradrenaline, phenylephrine, etc) can be life saving.2 This practice is supported by several case reports,3 4 5 predominantly in the anaesthesiac literature, and our subsequent unpublished experience.
After its independent review of the literature, the Resuscitation Council has also chosen to support the use of α agonists in anaphylaxis when adrenaline and fluids have not been successful. We hope that adjunctive treatment with α agonists, either by intravenous bolus or titrated infusion, may at least be considered by colleagues faced with such a dire situation.
Cite this as: BMJ 2008;337:a600
Competing interests: None declared.